AR104751A1 - Derivado de urea o una sal de este aceptable desde el punto de vista farmacológico - Google Patents
Derivado de urea o una sal de este aceptable desde el punto de vista farmacológicoInfo
- Publication number
- AR104751A1 AR104751A1 ARP160101520A ARP160101520A AR104751A1 AR 104751 A1 AR104751 A1 AR 104751A1 AR P160101520 A ARP160101520 A AR P160101520A AR P160101520 A ARP160101520 A AR P160101520A AR 104751 A1 AR104751 A1 AR 104751A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituents
- optionally
- group
- aromatic heterocyclyl
- heterocyclyl group
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 title 1
- 239000004202 carbamide Substances 0.000 title 1
- 230000000144 pharmacologic effect Effects 0.000 title 1
- 125000001424 substituent group Chemical group 0.000 abstract 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 150000003672 ureas Chemical class 0.000 abstract 2
- 208000014085 Chronic respiratory disease Diseases 0.000 abstract 1
- 101000818546 Homo sapiens N-formyl peptide receptor 2 Proteins 0.000 abstract 1
- 102100021126 N-formyl peptide receptor 2 Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010029216 Nervousness Diseases 0.000 abstract 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000024777 Prion disease Diseases 0.000 abstract 1
- 208000005074 Retroviridae Infections Diseases 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 206010002022 amyloidosis Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000003959 neuroinflammation Effects 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 230000036407 pain Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 208000013223 septicemia Diseases 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/26—Oxygen atoms attached in position 2 with hetero atoms or acyl radicals directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/22—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Un derivado de urea o una sal de este aceptable desde el punto de vista farmacológico que tienen un efecto agonista de un receptor del péptido formilo tipo 1 (en adelante abreviado como FPRL1), una composición farmacéutica que contiene el derivado de urea o la sal de este aceptable desde el punto de vista farmacológico. Útiles para el tratamiento, la prevención o la supresión de enfermedades inflamatorias, enfermedades de las vías respiratorias crónicas, tipos de cáncer, septicemia, síntomas alérgicos, infección por retrovirus VIH, trastornos circulatorios, neuroinflamación, trastornos nerviosos, dolores, enfermedades prionósicas, amiloidosis, trastornos inmunitarios, y similares. Reivindicación 1: Un compuesto caracterizado porque está representado por la fórmula general (1) o una sal de este aceptable desde el punto de vista farmacológico: en donde, en la fórmula (1), Ar¹ es un grupo fenilo que tiene opcionalmente sustituyentes, un grupo heterociclilo aromático monocíclico que tiene opcionalmente sustituyentes, o un grupo heterociclilo aromático bicíclico que tiene 9 ó 10 átomos y tiene opcionalmente sustituyentes; Ar² es un grupo fenilo que tiene opcionalmente sustituyentes (siempre que cuando A es el resto de fórmula A1, el grupo fenilo cuyos sustituyentes son solamente átomos de halógeno sea excluido), un grupo heterociclilo aromático monocíclico que tiene opcionalmente sustituyentes, o un grupo heterociclilo aromático bicíclico que tiene 9 ó 10 átomos y tiene opcionalmente sustituyentes; A es un grupo seleccionado del grupo que consiste en A1), A2), A3), A4) y A5) del grupo de fórmulas (2); en donde R¹ y R² son independientemente un átomo de hidrógeno o un grupo C₁₋₆ alquilo que tiene opcionalmente sustituyentes, o R¹ y R² juntos forman un grupo C₂₋₆ alquileno; R³ es un átomo de hidrógeno o un grupo C₁₋₆ alquilo que tiene opcionalmente sustituyentes; X es un átomo de oxígeno, un átomo de azufre o SO₂; B es un grupo heterociclilo que tiene opcionalmente sustituyentes; y cada átomo de carbono marcado con un asterisco es un átomo de carbono asimétrico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015107227 | 2015-05-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR104751A1 true AR104751A1 (es) | 2017-08-09 |
Family
ID=56121143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160101520A AR104751A1 (es) | 2015-05-27 | 2016-05-26 | Derivado de urea o una sal de este aceptable desde el punto de vista farmacológico |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10525058B2 (es) |
| EP (1) | EP3331884B1 (es) |
| JP (1) | JP6746613B2 (es) |
| KR (1) | KR20180006450A (es) |
| CN (2) | CN107849049B (es) |
| AR (1) | AR104751A1 (es) |
| AU (1) | AU2016266190A1 (es) |
| BR (1) | BR112017024966A2 (es) |
| CA (1) | CA2987235A1 (es) |
| CL (1) | CL2017002987A1 (es) |
| CO (1) | CO2017013101A2 (es) |
| EA (1) | EA201792382A1 (es) |
| ES (1) | ES2814126T3 (es) |
| IL (1) | IL255823A (es) |
| MX (1) | MX2017015040A (es) |
| PE (1) | PE20180234A1 (es) |
| TW (1) | TW201702226A (es) |
| WO (1) | WO2016189876A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102772801B1 (ko) | 2015-12-10 | 2025-02-24 | 브리스톨-마이어스 스큅 컴퍼니 | 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 |
| JP2020015664A (ja) * | 2016-11-21 | 2020-01-30 | 宇部興産株式会社 | 含窒素多環式ヘテロ環誘導体 |
| CN110997661B (zh) | 2017-06-09 | 2023-03-31 | 百时美施贵宝公司 | 环丙基脲甲酰肽2受体和甲酰肽1受体激动剂 |
| US11186544B2 (en) | 2017-06-09 | 2021-11-30 | Bristol-Myers Squibb Company | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| KR102615095B1 (ko) * | 2017-06-09 | 2023-12-15 | 브리스톨-마이어스 스큅 컴퍼니 | 피페리디논 포르밀 펩티드 2 수용체 효능제 |
| KR102615099B1 (ko) * | 2017-06-09 | 2023-12-15 | 브리스톨-마이어스 스큅 컴퍼니 | 아릴 헤테로시클릭 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 |
| KR102765631B1 (ko) * | 2017-10-04 | 2025-02-11 | 베리카 파마슈티컬스 인크. | 칸타리딘의 합성 |
| MY204384A (en) | 2018-03-05 | 2024-08-27 | Bristol Myers Squibb Co | Phenylpyrrolidinone formyl peptide 2 receptor agonists |
| AR114383A1 (es) * | 2018-03-09 | 2020-08-26 | Gruenenthal Gmbh | Piperidinas o piperidonas sustituidas con urea y fenilo |
| US12281108B2 (en) | 2018-11-26 | 2025-04-22 | Bristol-Myers Squibb Company | Pyrrolidinone derivatives as formyl peptide 2 receptor agonists |
| JP2024507672A (ja) * | 2021-01-21 | 2024-02-21 | ベイジン・ティアンタン・ホスピタル | Ｆｐｒ１のモジュレーター及びそれを使用する方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US13001A (en) | 1855-06-05 | Method of composing- music | ||
| CA2544983A1 (en) | 2003-11-07 | 2005-05-26 | Acadia Pharmaceuticals Inc. | Use of the lipoxin receptor, fprl1, as a tool for identifying compounds effective in the treatment of pain and inflammation |
| AR069650A1 (es) | 2007-12-14 | 2010-02-10 | Actelion Pharmaceuticals Ltd | Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano |
| EP2225231B1 (en) | 2007-12-18 | 2011-08-17 | Actelion Pharmaceuticals Ltd. | Aminotriazole derivatives as alx agonists |
| WO2010143158A1 (en) | 2009-06-12 | 2010-12-16 | Actelion Pharmaceuticals Ltd | Oxazole and thiazole derivatives as alx receptor agonists |
| EP2585054A1 (en) | 2010-06-24 | 2013-05-01 | Allergan, Inc. | Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity |
| WO2012066488A2 (en) | 2010-11-17 | 2012-05-24 | Actelion Pharmaceuticals Ltd | Bridged spiro[2.4]heptane ester derivatives |
| EP2646030A1 (en) | 2010-12-03 | 2013-10-09 | Allergan, Inc. | Pharmaceutical compositions comprising 3,4- dihydroisoquinolin-2(1 h)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity |
| AU2011340103A1 (en) | 2010-12-07 | 2013-07-25 | Actelion Pharmaceuticals Ltd. | Hydroxylated aminotriazole derivatives as ALX receptor agonists |
| TWI523853B (zh) | 2010-12-07 | 2016-03-01 | 艾克泰聯製藥有限公司 | 作為ａｌｘ受體促效劑之唑基－甲醚衍生物 |
| EP2673263A1 (en) | 2011-02-11 | 2013-12-18 | Allergan, Inc. | Novel 1-(1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives as n-formyl peptide receptor like-1 (fprl-1) receptor modulators |
| US8653299B2 (en) | 2011-03-17 | 2014-02-18 | Allergan, Inc. | Dihydronaphthalene and naphthalene derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators |
| SG10201913053QA (en) * | 2011-05-13 | 2020-03-30 | Array Biopharma Inc | Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors |
| AU2012329098B2 (en) | 2011-10-26 | 2017-08-03 | Allergan, Inc. | Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators |
| WO2013063214A1 (en) * | 2011-10-27 | 2013-05-02 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| US8492556B2 (en) | 2011-11-10 | 2013-07-23 | Allergan, Inc. | 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators |
| US8541577B2 (en) | 2011-11-10 | 2013-09-24 | Allergan, Inc. | Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators |
| MA37618B1 (fr) | 2012-05-16 | 2017-08-31 | Actelion Pharmaceuticals Ltd | Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx |
| CN104284887B (zh) | 2012-05-16 | 2016-06-22 | 埃科特莱茵药品有限公司 | 作为alx受体激动剂的经1-(对-甲苯基)环丙基取代的桥联螺[2.4]庚烷衍生物 |
| AR096686A1 (es) | 2013-06-25 | 2016-01-27 | Actelion Pharmaceuticals Ltd | Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx |
| US9771357B2 (en) | 2013-07-09 | 2017-09-26 | Ono Pharmaceutical Co., Ltd. | ALXR agonist compound |
| EP3022174B1 (en) | 2013-07-16 | 2018-09-05 | Allergan, Inc. | Derivatives of n-urea substituted amino acids as formyl peptide receptor modulators |
| US9533964B2 (en) | 2013-07-18 | 2017-01-03 | Actelion Pharmaceuticals Ltd. | Piperazine substituted bridged spiro[2.4]heptane derivatives as ALX receptor agonists |
| AR097279A1 (es) | 2013-08-09 | 2016-03-02 | Actelion Pharmaceuticals Ltd | Derivados de benzimidazolil-metil urea como agonistas del receptor de alx |
| NZ752095A (en) * | 2013-11-28 | 2022-07-01 | Kyorin Seiyaku Kk | Urea derivative or pharmacologically acceptable salt thereof |
| US10136420B2 (en) * | 2014-09-26 | 2018-11-20 | Nokia Of America Corporation | Methods and systems for signaling dynamic network assisted information to a user equipment |
| WO2016095089A1 (en) | 2014-12-15 | 2016-06-23 | Merck Sharp & Dohme Corp. | Erk inhibitors |
-
2016
- 2016-05-26 MX MX2017015040A patent/MX2017015040A/es unknown
- 2016-05-26 BR BR112017024966A patent/BR112017024966A2/pt not_active Application Discontinuation
- 2016-05-26 EP EP16729077.4A patent/EP3331884B1/en active Active
- 2016-05-26 PE PE2017002476A patent/PE20180234A1/es unknown
- 2016-05-26 CN CN201680041960.XA patent/CN107849049B/zh not_active Expired - Fee Related
- 2016-05-26 JP JP2017560628A patent/JP6746613B2/ja not_active Expired - Fee Related
- 2016-05-26 EA EA201792382A patent/EA201792382A1/ru unknown
- 2016-05-26 AU AU2016266190A patent/AU2016266190A1/en not_active Abandoned
- 2016-05-26 KR KR1020177036827A patent/KR20180006450A/ko not_active Withdrawn
- 2016-05-26 WO PCT/JP2016/002557 patent/WO2016189876A1/en not_active Ceased
- 2016-05-26 US US15/576,350 patent/US10525058B2/en not_active Expired - Fee Related
- 2016-05-26 ES ES16729077T patent/ES2814126T3/es active Active
- 2016-05-26 TW TW105116494A patent/TW201702226A/zh unknown
- 2016-05-26 AR ARP160101520A patent/AR104751A1/es unknown
- 2016-05-26 CN CN202110177501.7A patent/CN113185452A/zh active Pending
- 2016-05-26 CA CA2987235A patent/CA2987235A1/en not_active Abandoned
-
2017
- 2017-11-21 IL IL255823A patent/IL255823A/en unknown
- 2017-11-24 CL CL2017002987A patent/CL2017002987A1/es unknown
- 2017-12-20 CO CONC2017/0013101A patent/CO2017013101A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112017024966A2 (pt) | 2018-08-07 |
| PE20180234A1 (es) | 2018-01-31 |
| WO2016189876A1 (en) | 2016-12-01 |
| US20180207153A1 (en) | 2018-07-26 |
| MX2017015040A (es) | 2018-08-14 |
| EA201792382A1 (ru) | 2018-04-30 |
| JP6746613B2 (ja) | 2020-08-26 |
| AU2016266190A1 (en) | 2018-01-18 |
| EP3331884A1 (en) | 2018-06-13 |
| JP2018521005A (ja) | 2018-08-02 |
| ES2814126T3 (es) | 2021-03-26 |
| CL2017002987A1 (es) | 2018-05-25 |
| IL255823A (en) | 2018-01-31 |
| TW201702226A (zh) | 2017-01-16 |
| US10525058B2 (en) | 2020-01-07 |
| EP3331884B1 (en) | 2020-06-17 |
| CN107849049B (zh) | 2021-03-16 |
| CA2987235A1 (en) | 2016-12-01 |
| CN113185452A (zh) | 2021-07-30 |
| CO2017013101A2 (es) | 2018-05-21 |
| CN107849049A (zh) | 2018-03-27 |
| KR20180006450A (ko) | 2018-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR104751A1 (es) | Derivado de urea o una sal de este aceptable desde el punto de vista farmacológico | |
| DOP2019000187A (es) | Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo | |
| NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
| PE20212077A1 (es) | Nuevos compuestos sulfonamida de carboxamida | |
| UY36056A (es) | “compuestos de heteroarilo o arilo bicíclicos fusionados “. | |
| MX375323B (es) | Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos. | |
| MD3416631T2 (ro) | Agenți terapeutici pentru bolile neurodegenerative | |
| BR112015018509A2 (pt) | compostos de imidazo piridina | |
| EP3325487A4 (en) | FORMULATION FOR SOFT ANTICHOLINERGIC ANALOGUE | |
| CL2019001041A1 (es) | Compuestos terapéuticos y métodos para utilizarlos. | |
| CY1124413T1 (el) | Ανταγωνιστες του υποδοχεα cgrp | |
| MX388592B (es) | Compuestos y metodos terapeuticos. | |
| CY1121345T1 (el) | Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης | |
| JO3742B1 (ar) | مركب بيرانو داي بيريدين | |
| EA201692298A1 (ru) | Производные карбоксамидов | |
| MX394782B (es) | Compuestos para el tratamiento de enfermedades asociadas con una disfunción mitocondrial. | |
| EA201792264A1 (ru) | Способы лечения воспалительных заболеваний | |
| EA201791480A1 (ru) | Новые производные бензимидазола в качестве антигистаминных агентов | |
| CY1122375T1 (el) | Συμπυκνωμενα με τετραϋδροφουρανιο αμινοϋδροθειαζινικα αναλογα τα οποια ειναι χρησιμα στη θεραπεια της νοσου toy alzheimer | |
| CY1123185T1 (el) | Παραγωγα ινδολιου | |
| CO2019013254A2 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
| MX387920B (es) | Peptidos antagonistas de prgc. | |
| EA201790020A1 (ru) | Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний | |
| CY1125090T1 (el) | Ενωση γουανιδινης αντικαταστασης | |
| MX2018000677A (es) | Derivado de urea y uso del mismo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |